

RIBOMIC Announces Publication Highlighting Novel Approach to Generate Aptamer using AI in the Nature Computational Science

TOKYO, June 3, 2022 - RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TYO:4591), today announced the publication of the first ever, innovative computational approach to generate aptamers in the journal *Nature Computational Science*. The technology, named "RaptGen", exploits a deep generative model for aptamer discovery and was developed in collaboration with Professor Michiaki Hamada at the Graduate School of Advanced Science and Engineering, Waseda University. By applying RaptGen, RIBOMIC aims to reinforce the company's core drug discovery platform and to shorten the drug discovery period.

Journal name	Nature Computational Science
Article title	Generative aptamer discovery using RaptGen
Article URL	https://www.nature.com/articles/s43588-022-00249-6

ABOUT RIBOMIC

RIBOMIC is a clinical stage bio-pharmaceutical company specializing in the discovery and development of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company's core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, rare disease of short stature in children and many other diseases.

See RIBOMIC website for more information.

<https://www.ribomic.com/eng/>

Forward-Looking Statements

This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.

Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information:

RIBOMIC Inc.

Finance and Accounting

ir.inquiry@ribomic.com